Bloomberg cites sources close to Italy's Sigma-Tau who say that the company is considering selling a stake in the biotech following the death of its founder. Four Partners is advising the company, which is reportedly considering a deal that would value the company at $1.4 billion. Sigma-Tau has a pipeline of drugs in development for rare and neglected ailments. Story